Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Deyab, Gia; Hokstad, Ingrid; Whist, Jon Elling; Småstuen, Milada Cvancarova; Agewall, Stefan; Lyberg, Torstein; Bottazzi, Barbara; Meroni, Pier Luigi; Leone, Roberto; Hjeltnes, Gunnbjørg; Hollan, Ivana

doi:10.1371/journal.pone.0169830

Cited by 22 publications

(19 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the PTX3 levels were mainly affected by active vasculitis, but not the prednisolone dose [ 20 ]. In addition, methotrexate seems not to affect PTX3 level in TAK, and it was proved not to influence PTX3 in inflammatory rheumatic disease [ 12 , 33 ]. However anti-IL-6 showed contrary results.…”

Section: Discussionmentioning

confidence: 99%

Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis

Wen

Hou

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Aims Whether the circulating levels of pentraxin 3 (PTX3), an acute phase reactant (APR), are higher in active Takayasu arteritis (TAK), and if so, whether PTX3 is more accurate than C-reactive protein (CRP) in TAK activity assessment has been investigated in this study. Study design Research works such as PubMed, Embase, ScienceDirect, Cochrane Library, and two Chinese literature databases (CNKI and WanFang) were searched for studies conducted till August 30th, 2019. Two investigators searched the studies independently, who evaluated the quality of the study using the Newcastle–Ottawa scale (NOS) and extracted data. Pooled standard mean difference (SMD) and diagnostic indexes, with a 95% confidence interval (CI), were calculated using a random-effect model. Results Totally, 8 studies involving 473 TAK (208 active and 265 inactive TAK) patients and 252 healthy controls were eventually included in the meta-analysis. PTX3 level in the blood in active TAK patients were found to be higher than that in dormant TAK with pooled SMD of 0.761 (95% CI = 0.38–1.14, p<0.0001; I2 = 68%, p of Q test = 0.003). And there was no publication bias. Among the 8 studies, 5 studies identified active TAK with both PTX3 and CRP. The pooled sensitivity, specificity, and AUC values of PTX3 in active TAK diagnosis were higher than those of CRP (0.78 [95% CI = 0.65–0.87] vs. 0.66 [95% CI = 0.53–0.77], p = 0.012; 0.85 [95% CI = 0.77–0.90] vs. 0.77 [95% CI = 0.56–0.90], p = 0.033; 0.88 [95% CI = 0.85–0.90] vs. 0.75 [95% CI = 0.71–0.79], p < 0.0001). It showed potential publication bias using Egger’s test (p of PTX3 = 0.031 and p of CRP = 0.047). Conclusions PTX3 might be better than CRP in the assessment of TAK activity. Yet, it should be cautious before clinical use for moderate heterogeneity and potential publication bias of the meta-analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis

Wen

Hou

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Our previous article based on the same patient sample demonstrated that MTX and anti-TNF ± MTX treatment significantly reduced inflammatory activity (determined by ESR, CRP, WBC count, PGA, and PtGA) both at 6 weeks and at 6 months compared to baseline [ 16 ]. This may indicate that both treatment regimens have a longstanding effect on inflammation, but only MTX (in patients potentially responding to it) has a prolonged beneficial effect on the endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

“…All patients in PSARA, an observational study, had been included at the Lillehammer Hospital for Rheumatic Diseases as described elsewhere [ 16 ]. Briefly, the inclusion criteria were: males and females with an age range 18–80 years; and PsA according to the Moll and Wright 1973 criteria [ 17 ], AS according to the modified New York diagnostic criteria for AS [ 18 ], or RA according to the ACR 1987 criteria [ 19 ], and clinical indication for starting with either MTX monotherapy or anti-TNF treatment with or without MTX comedication (anti-TNF ± MTX).…”

Section: Methodsmentioning

confidence: 99%

Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis

Deyab

Hokstad²,

Whist

et al. 2017

Arthritis Res Ther

Self Cite

View full text Add to dashboard Cite

BackgroundInflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis. One of the first stages in atherogenesis is endothelial dysfunction (ED). Therefore, we aimed to compare endothelial function (EF) in patients with IA, and to examine the effects of methotrexate (MTX) monotherapy and antitumor necrosis factor (anti-TNF) treatment with or without MTX comedication (anti-TNF ± MTX) on EF.MethodsFrom the PSARA observational study, all patients with RA (n = 64), PsA (n = 29), and AS (n = 20) were evaluated for EF. In patients with ED at baseline (n = 40), we evaluated changes in the Reactive Hyperemic Index (RHI) after 6 weeks and 6 months of antirheumatic therapy.ResultsIn IA patients with ED, RHI significantly improved after 6 weeks (p < 0.001) and 6 months (p < 0.001) of treatment, independent of changes in disease activity parameters. After 6 months, RHI had improved more in the MTX group than in the anti-TNF ± MTX group, and the difference remained statistically significant after adjustments for potential confounders. Among patients with active RA, AS, and PsA, those with AS appeared to have the worst endothelial function, although they were the youngest.ConclusionTreatment with MTX and anti-TNF ± MTX was associated with a relatively fast improvement of EF in IA patients with ED, independent of change in disease activity. Therefore, modes of action other than the anti-inflammatory effect may contribute to the EF improvement. After 6 months, the EF improvement was more pronounced in the MTX group than in the anti-TNF ± MTX group.Trial registrationClinicaltrials, NCT00902005. Registered on 13 May 2009.

show abstract

“…This observational prospective study is based on all SpA patients (31 PsA, and 20 AS) who completed 6 months follow-up in the PSARA (PSoriatic arthritis, Ankylosing spondylitis, Rheumatoid Arthritis) study, described in detail elsewhere [17]. Patients were recruited from October 2008 to May 2010.…”

Section: Methodsmentioning

confidence: 99%

Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers. Methods From PSARA, a prospective observational study, we examined 51 SpA patients (31 psoriatic arthritis (PsA), and 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX) (n = 10), or MTX monotherapy (n = 16). Complement activation was determined by the soluble terminal complement complex (sC5b-9), inflammation by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and endothelial function by finger plethysmography (Endopat) at baseline, after 6 weeks and 6 months of treatment. Results SpA patients had sC5b-9 levels at (PsA) or above (AS) the upper limit of the estimated reference range. Median sC5b-9 levels decreased significantly from baseline to 6 weeks, with no significant difference between the AS and PsA group. Notably, a significant reduction in sC5b-9 was observed after administration of TNF inhibitor ± MTX, whereas no significant changes were observed in patients treated with MTX alone. Between 6 weeks and 6 months, sC5b-9 remained stable across all subgroups. Reduction in sC5b-9 was independently related to decreased ESR and CRP, and to increased high density cholesterol and total cholesterol. Reduction in sC5b-9 from baseline to 6 weeks was associated with improved EF in age and gender adjusted analyses. Conclusion TNF-inhibition, but not MTX monotherapy, led to rapid and sustained reduction of complement activation in SpA. Thus, the observed decrease in cardiovascular morbidity in patients treated with TNF-inhibitors might be partly due to its beneficial effect on complement. Trial registration Clinical Trials ( NCT00902005 ), retrospectively registered on the 14 th of May 2009.

show abstract

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Cited by 22 publications

References 45 publications

Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis

Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis

Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis

Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study

Contact Info

Product

Resources

About